Evidence map›Paper›PMID 37217548›Full record

ArticleScientific reports2023

A blood and bronchoalveolar lavage protein signature of rapid FEV

Katarina M DiLillo, Katy C Norman, Christine M Freeman, Stephanie A Christenson, Neil E Alexis, Wayne H Anderson, Igor Z Barjaktarevic, R Graham Barr, Alejandro P Comellas, Eugene R Bleecker and 24 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Omic Risk Scores are Associated with COPD-related Traits Across Three Cohorts.medRxiv : the preprint server for health sciences · 2025
    Article
  7. Review
  8. Article
  9. Dynamic and prognostic proteomic associations with FEVmedRxiv : the preprint server for health sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 18 institutions in 1 country.

Katarina M DiLilloDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Katy C NormanDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Christine M FreemanResearch Service, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Stephanie A ChristensonDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA.
Neil E AlexisCenter for Environmental Medicine, Asthma, and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Wayne H AndersonMarsico Lung Institute/Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Igor Z BarjaktarevicDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
R Graham BarrDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
Alejandro P ComellasDivision of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, IA, USA.
Eugene R BleeckerDivision of Genetics, Genomics and Precision Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Richard C BoucherMarsico Lung Institute/Cystic Fibrosis Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
David J CouperCollaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gerard J CrinerDepartment of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA, USA.
Claire M DoerschukMarsico Lung Institute/Cystic Fibrosis Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
J Michael WellsDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
MeiLan K HanDivision of Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Eric A HoffmanDepartment of Radiology, University of Iowa, Iowa City, IA, USA.
Nadia N HanselDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Annette T HastieDepartment of Internal Medicine, Wake Forest School of Medicine, Atrium Health, Wake Forest Baptist, Winston Salem, NC, USA.
Robert J KanerDepartment of Medicine, Weill Cornell Medical Center, New York, NY, USA.
Jerry A KrishnanDivision of Pulmonary, Critical Care, Sleep and Allergy, University of Illinois at Chicago, Chicago, IL, USA.
Wassim W LabakiDivision of Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Fernando J MartinezDepartment of Medicine, Weill Cornell Medical Center, New York, NY, USA.
Deborah A MeyersDivision of Genetics, Genomics and Precision Medicine, University of Arizona Health Sciences, Tucson, AZ, USA.
Wanda K O'NealMarsico Lung Institute/Cystic Fibrosis Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Victor E OrtegaDepartment of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Scottsdale, AZ, USA.
Robert PaineDivision of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA.
Stephen P PetersDepartment of Internal Medicine, Wake Forest School of Medicine, Atrium Health, Wake Forest Baptist, Winston Salem, NC, USA.
Prescott G WoodruffDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA.
Christopher B CooperDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Russell P BowlerDivision of Pulmonary and Critical Care, National Jewish Health, Denver, CO, USA.
Jeffrey L CurtisDivision of Pulmonary & Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Kelly B ArnoldDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. kbarnold@umich.edu.
SPIROMICS investigators
University of Michigan–Ann Arbor · USUniversity of North Carolina at Chapel Hill · USAtrium Health Wake Forest Baptist · USCornell University · USUniversity of Arizona · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Iowa · USColumbia University Irving Medical Center · USJohns Hopkins Medicine · USLung Institute · USMayo Clinic in Arizona · USNational Jewish Health · USTemple University · USUniversity of Alabama at Birmingham · USUniversity of Illinois Chicago · USUniversity of Utah · USVA Ann Arbor Healthcare System · US

Funding

Pulmonary Toxicology FacilityP30ES005605 · UNIVERSITY OF IOWA · 1990 to 2025
$8.8M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · UNIVERSITY OF ARIZONA · 1994 to 2025
$7.3M
Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPDR01HL144849 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kelly Arnold · 2023 to 2023
$320k
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2022 to 2025
$242k
Regulatory T Cell Inhibition of Natural Killer Cells in COPDI01CX001553 · VA · VETERANS HEALTH ADMINISTRATION · 2023 to 2025
–
CSRD VA I01 CX001553NHLBI NIH HHS K24 HL137013NHLBI NIH HHS R01 HL095432NHLBI NIH HHS R01 HL129937NHLBI NIH HHS R01 HL137995NHLBI NIH HHS R01 HL144849NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NIEHS NIH HHS P30 ES005605NIEHS NIH HHS P30 ES006694
6 · The paper itself

Abstract

Accelerated progression of chronic obstructive pulmonary disease (COPD) is associated with increased risks of hospitalization and death. Prognostic insights into mechanisms and markers of progression could facilitate development of disease-modifying therapies. Although individual biomarkers exhibit some predictive value, performance is modest and their univariate nature limits network-level insights. To overcome these limitations and gain insights into early pathways associated with rapid progression, we measured 1305 peripheral blood and 48 bronchoalveolar lavage proteins in individuals with COPD [n = 45, mean initial forced expiratory volume in one second (FEV

Indexed as

LungPulmonary Disease, Chronic ObstructiveBiomarkersBronchoalveolar LavageDisease ProgressionForced Expiratory VolumeHumansSmokingBiomarkers

Identifiers

PMID37217548
PMCPMC10203309
OpenAlexW4377291411

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.